T-cell responses to hepatitis B surface antigen in lung transplant recipients

Pharmacotherapy

Volumn 27, Issue 9 I, 2007, Pages 1248-1252

  Hayney, Mary S ^a   Wiegert, Nicholas A ^a   Pelsue, Frances L ^a   Fohl, Renee M ^a   Jankowska Gan, Ewa ^b   Love, Robert B ^c   Burlingham, William J ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Antibody response; Hepatitis B vaccine; Immunizations; Lung transplantation; T cell; Vaccine response

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; SODIUM CHLORIDE; TETANUS TOXOID;

ADULT; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOOT EDEMA; FOOT PAD; GRAFT RECIPIENT; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOASSAY; LUNG TRANSPLANTATION; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROPHYLAXIS; SCID MOUSE; T LYMPHOCYTE; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ADULT; AGE FACTORS; ANIMALS; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOLOGIC MEMORY; LEUKOCYTES, MONONUCLEAR; LUNG TRANSPLANTATION; MALE; MICE; MICE, SCID; MIDDLE AGED; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TIME FACTORS;

EID: 34548304878     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.9.1248     Document Type: Article

References (17)

1. Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines, 3rd ed. Philadelphia: WB Saunders Co.; 1999:158-82.
2. Centers for Disease Control and Prevention. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United Stales through universal childhood vaccination. Recommendations of the immunization practices advisory committee (ACIP). MMWR Morb Mortal Wkly Rep 1991;40(RR-13):1-25.
3. West DJ, Calandra GB. Vaccine-induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996;14:1019-27.
4. Wismans PJ, van Hattum J, De Gast GC, et al. The spot-ELISA: a sensitive in vitro method to study the immune response to hepatitis B surface antigen. Clin Exp Immunol 1989;78:75-9.
5. Roque-Afonso AM, Feray C, Samuel D, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002;50:95-9.
6. Carrodeguas L, Orosz CG, Waldman WJ, Sedmak DD, Adams PW, VanBuskirk AM. Trans vivo analysis of human delayed-type hypersensitivity reactivity. Hum Immunol 1999;60:640-51.
7. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000;106:145-55.
8. Hayney MS, Welter DL, Reynolds AM, Francois M, Love RB. High-dose hepatitis B vaccine in patients waiting for lung transplantation. Pharmacotherapy 2003;23:555-60.
9. Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clin Microbiol Rev 1998;11:1-26.
10. Horlander JC, Boyle N, Manam R, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999;318:304-7.
11. Jilg W, Schmidt M, Weinel B, et al. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. J Hepatol 1986;3:190-5.
12. Keet IP, van Doornum G, Safary A, Coutinho RA. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men [letter]. AIDS 1992;6:509-10.
13. Seaworth B, Drucker J, Starling J, Drucker R, Stevens C, Hamilton J. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis 1988;157:332-7.
14. Wismans PJ, van Hattum J, de Gast GC, et al. A prospective study of in vitro anti-HBs producing B cells (spot-ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls. J Med Virol 1991;35:216-22.
15. Roome AJ, Walsh SJ, Cartter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270:2931-4.
16. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the advisory committee on immunization practices (ACIP) part II: immunization of adults. MMWR Morb Mortal Wkly Rep 2006;55(RR-16):1-33.
17. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006;24:572-7.